MAPK inhibitor sensitivity scores predict sensitivity driven by the immune infiltration in pediatric low-grade gliomas

Abstract excerpt

Pediatric low-grade gliomas (pLGG) show heterogeneous responses to MAPK inhibitors (MAPKi) in clinical trials. Thus, more complex stratification biomarkers are needed to identify patients likely to benefit from MAPKi therapy. Here, we identify MAPK-related genes enriched in MAPKi-sensitive cell lines using the GDSC dataset and apply them to calculate class-specific MAPKi sensitivity scores (MSSs) via...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glioma Diagnosis and Treatment
• Share to MicroRNA in disease regulation
• Share to Neuroinflammation and Neurodegeneration Mechanisms